Clinical Trial Update: Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating Emicizumab (Hemlibra) for severe Von Willebrand disease (type 3) and for patients with concomitant Von Willebrand disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia
• Von Willebrand Disease Type

Drugs mentioned

• Hemlibra (emicizumab)

Snippet

Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois | Conditions: Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia | Phase 1 | Status: RECRUITING